Tadbiri S, et al. - This multicentre cohort study was performed to evaluate the effect of vedolizumab therapy on extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) in a large real-life experience cohort. Collected evidence represented that vedolizumab therapy was commonly correlated with improvement in EIM. This was correlated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis could occur upon vedolizumab therapy.